Clinical Trial Update: Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II trial evaluating MEDI4736 (durvalumab) in various combinations for metastatic pancreatic ductal adenocarcinoma has completed phase 1/2 with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• MEDI4736 (Durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-08-14